Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements

Xenobiotica

Volumn 38, Issue 3, 2008, Pages 264-280

  Foti, R S ^a   Dickmann, L J ^a   Davis, J A ^a   Greene, R J ^a   Hill, J J ^a   Howard, M L ^a   Pearson, J T ^a   Rock, D A ^a   Tay, J C ^a   Wahlstrom, J L ^a   Slatter, J G ^a  

^a AMGEN INC   (United States)

Author keywords

CYP inhibition; CYP2C18; CYP2C19; CYP2C8; CYP2C9; Cytochrome P450 (CYP) 1A2; Drug drug interactions; Glucuronidation; Hepatotoxicity; Hydroxylation; Nutritional supplement; UGT1A3; Uridine diphosphate glucuronosyltransferase (UGT) 1A1; Usnic acid

Indexed keywords

BIOLOGICAL MARKER; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C18; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A3; OMEPRAZOLE; PHENOBARBITAL; RIFAMPICIN; USNIC ACID;

AEROBIC METABOLISM; ARTICLE; DRUG INTERACTION; DRUG METABOLISM; ENZYME POLYMORPHISM; ENZYME SUBSTRATE; GLUCURONIDATION; HUMAN; HUMAN CELL; HYPERBILIRUBINEMIA; LIVER CELL; LIVER INJURY; LIVER TOXICITY; MICROSOME; NUTRITIONAL SUPPORT; PLASMA; RISK FACTOR;

BENZOFURANS; CYTOCHROME P-450 ENZYME SYSTEM; DIETARY SUPPLEMENTS; DRUG INTERACTIONS; ENZYME INDUCTION; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; LIVER DISEASES; MICROSOMES, LIVER; MODELS, MOLECULAR; PROTEIN BINDING; RISK FACTORS; SUBSTRATE SPECIFICITY;

EID: 39349102354     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250701802514     Document Type: Article

References (51)

1. Abo-Khatwa AN, al-Robai AA, al-Jawhari DA. 1996. Lichen acids as uncouplers of oxidative phosphorylation of mouse-liver mitochondria. Natural Toxins 4(2):96-102.
2. Arneborn P, Jansson A, Bottiger Y. 2005. Acute hepatitis in a woman after intake of slimming pills bought via Internet. Lakartidningen 102(28-29):2071-2072.
3. Blume H, Donath F, Warnke A, Schug BS. 2006. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Safety 29(9):769-784.
4. Broksa B, Sturdikova M, Pronayova N, Liptaj T. 1996. (-)-Usnic acid and its derivatives. Their inhibition of fungal growth and enzyme activity. Pharmazie 51(3):195-196.
5. Campanella L, Delfini M, Ercole P, Iacoangeli A, Risuleo G. 2002. Molecular characterization and action of usnic acid: A drug that inhibits proliferation of mouse polyomavirus in vitro and whose main target is RNA transcription. Biochimie 84(4):329-334.
6. Cardarelli M, Serino G, Campanella L, Ercole P, De Cicco Nardone F, Alesiani O, Rossiello F. 1997. Antimitotic effects of usnic acid on different biological systems. Cell and Molecular Life Sciences 53(8):667-672.
7. Cocchietto M, Skert N, Nimis PL, Sava G. 2002. A review on usnic acid, an interesting natural compound. Naturwissenschaften 89(4):137-146.
8. Colman E. 2007. Dinitrophenol and obesity: An early twentieth-century regulatory dilemma. Regulatory Toxicology and Pharmacology 48(2):115-117.
9. Cornwell P, Slatter JG, De Souza AT, Rockett JC, Caguyong MJ, He YD, Dai X, Cheng O, Ulrich RG. 2006. Investigation of the hepatotoxicity of usnic acid using a compendium of rat liver gene expression profiles. Paper presented at the Society of Toxicology 45th Annual Meeting, San Diego, CA, USA, 5-9 March 2006.
10. Correche ER, Enriz RD, Piovano M, Garbarino J, Gomez-Lechon MJ. 2004. Cytotoxic and apoptotic effects on hepatocytes of secondary metabolites obtained from lichens. Alternatives to Laboratory Animals 32(6):605-615.
11. Durazo FA, Lassman C, Han SH, Saab S, Lee NP, Kawano M, Saggi B, Gordon S, Farmer DG, Yersiz H, Goldstein RL, Ghobrial M, Busuttil RW. 2004. Fulminant liver failure due to usnic acid for weight loss. American Journal of Gastroenterology 99(5):950-952.
12. Elo H, Matikainen J, Pelttari E. 2007. Potent activity of the lichen antibiotic (+)-usnic acid against clinical isolates of vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus. Naturwissenschaften 94(6):465-468.
13. Estes JD, Stolpman D, Olyaei A, Corless CL, Ham JM, Schwartz JM, Orloff SL. 2003. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Archives of Surgery 138:852-858.
14. Favreau JT, Ryu ML, Braunstein G, Orshansky G, Park SS, Coody GL, Love LA, Fong T. 2002. Severe hepatotoxicity associated with the dietary supplement LipoKinetix. Annals of Internal Medicine 136(8):290-595.
15. Frankos VH. 2005. Nomination for usnic acid and Usnea barbata herb. National Toxicology Program. Washington, DC: Food and Drug Administration, Division of Dietary Supplement Programs (available at: http:// ntp.niehs.nih.gov/ntp/htdocs/Chem_Background/ExSumPdf/UsnicAcid.pdf).
16. Gibson JE, Taylor DA. 2005. Can claims, misleading information, and manufacturing issues regarding dietary supplements be improved in the United States? Journal of Pharmacology and Experimental Therapeutics 314(3):939-944.
17. Ha-Duong NT, Dijols S, Marques-Soares C, Minoletti C, Dansette PM, Mansuy D. 2001. Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily. Journal of Medicinal Chemistry 25(44):3622-3631.
18. Han D, Matsumaru K, Rettori D, Kaplowitz N. 2004. Usnic acid-induced necrosis of cultured mouse hepatocytes: inhibition of mitochondrial function and oxidative stress. Biochemical Pharmacology 67(3):439-451.
19. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. 2007. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. Journal of the National Cancer Institute 99(17):1290-1295.
20. Hsu LM, Huang YS, Chang FY, Lee SD. 2005. 'Fat burner' herb, usnic acid, induced acute hepatitis in a family. Journal of Gastroenterology and Hepatology 20(7):1138-1139.
21. Indiana University School of Medicine. 2007. Drug Interactions Table. Indianapolis, IN: Indiana University School of Medicine (available at: http://medicine.iupui.edu/flockhart/table.htm).
22. Koparal AT, Tuylu BA, Turk H. 2006. In vitro cytotoxic activities of (+)-usnic acid and (-)-usnic acid on V79, A549, and human lymphocyte cells and their non-genotoxicity on human lymphocytes. Natural Product Research 20(14):1300-1307.
23. Krishna DR, Ramana DV, Mamidi NV. 1995. In vitro protein binding and tissue distribution of D(+) usnic acid. Drug -Metabolite-Drug Interactions 12(1):53-63.
24. Krishna DR, Venkataramana D. 1992. Pharmacokinetics of D(+)-usnic acid in rabbits after intravenous and oral administration. Drug Metabolism and Disposition 20(6):909-911.
25. Kristmundsdottir T, Aradottir HA, Ingolfsdottir K, Ogmundsdottir HM. 2002. Solubilization of the lichen metabolite (+)-usnic acid for testing in tissue culture. Journal of Pharmacy and Pharmacology 4(11):1447-1452.
26. Kumar KC, Muller K. 1999a. Lichen metabolites 1. Inhibitory action against leukotriene B4 biosynthesis by a nonredox mechanism. Journal of Natural Products 62(6):817-820.
27. Kumar KC, Muller K. 1999. Lichen metabolites 2. Antiproliferative and cytotoxic activity of gyrophoric, usnic and diffractaic acid on human keratinocyte growth. Journal of Natural Products 62(6):821-823.
28. Kuo IF, Chen J, Chang TKH. 2004. Effect of Ginkgo biloba extract on rat hepatic microsomal CYP1A activity: Role of ginkgolides, bilobalide, and flavonols. Canadian Journal of Physiology and Pharmacology 82(1):57-64.
29. Kutney JP, Baarschers WH, Chin O, Ebizuka Y, Hurley L, Leman JD, Salisbury PJ, Sanchez IH, Yee T, Bandoni RJ. 1977. Studies on the usnic-acid series: Part 8: The biodegradation of dextro usnic-acid by Mortierella isabellina. Canadian Journal of Chemistry 55:2930-2940.
30. Mayer M, O'Neill MA, Murray KE, Santos-Magalhaes NS, Carneiro-Leao AM, Thompson AM, Appleyard VC. 2005. Usnic acid: A non-genotoxic compound with anti-cancer properties. Anticancer Drugs 16(8):805-809.
31. Miners JO, Knights KM, Houston JB, Mackenzie PI. 2006. In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: Pitfalls and promises. Biochemical Pharmacology 71(11):1531-1539.
32. Nath A, Atkins WM. 2006. A theoretical validation of the substrate depletion approach to determining kinetic parameters. Drug Metabolism and Disposition 34:1433-1435.
33. Neff GW, Reddy KR, Durazo FA, Meyer D, Marrero R, Kaplowitz N. 2004. Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. Journal of Hepatology 41(6):1062-1064.
34. Obach RS, Reed-Hagen AE. 2002. Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metabolism and Disposition 30:831-837.
35. Odabasoglu F, Cakir A, Suleyman H, Aslan A, Bayir Y, Halici M, Kazaz C. 2006. Gastroprotective and antioxidant effects of usnic acid on indomethacin-induced gastric ulcer in rats. Journal of Ethnopharmacology 103(1):59-65.
36. Polson J, Lee WM. 2005. American Association for the Study of Liver Disease (AASLD) Position Paper: The management of acute liver failure. Hepatology 41(5):1179-1197.
37. Pramyothin P, Janthasoot W, Pongnimitprasert N, Phrukudom S, Ruangrungsi N. 2004. Hepatotoxic effect of (+)usnic acid from Usnea siamensis Wainio in rats, isolated rat hepatocytes and isolated rat liver mitochondria. Journal of Ethnopharmacology 90(2-3):381-387.
38. Rafanelli S, Bacchilega R, Stanganelli I, Rafanelli A. 1995. Contact dermatitis from usnic acid in vaginal ovules. Contact Dermatitis 33(4):271-272.
39. Rancan F, Rosan S, Boehm K, Fernandez E, Hidalgo ME, Quihot W, Rubio C, Boehm F, Piazena H, Oltmanns U. 2002. Protection against UVB irradiation by natural filters extracted from lichens. Journal of Photochemistry and Photobiology B 68(2-3):133-139.
40. Registry of Toxic Effects of Chemical Substances (RTECS). 2007. RTECS Database 2007 (available at: http://csi.micromedex.com/).
41. Rettie AE, Jones JP. 2005. Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annual Reviews in Pharmacology and Toxicology 45:477-494.
42. Sanchez W, Maple JT, Burgart LJ, Kamath PS. 2006. Severe hepatotoxicity associated with use of a dietary supplement containing usnic acid. Mayo Clinic Proceedings 81(4):541-544.
43. Schoepfer AM, Engel A, Fattinger K, Marbet UA, Criblez D, Reichen J, Zimmer. 2007. Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products. Journal of Hepatology 47(4):521-526.
44. Sheu M, Simpson EL, Law SV, Storrs FJ. 2006. Allergic contact dermatitis from a natural deodorant: A report of 4 cases associated with lichen acid mix allergy. Journal of the American Academy of Dermatology 55(2):332-337.
45. Takai M, Uehara Y, Beisler JA. 1979. Usnic acid derivatives as potential antineoplastic agents. Journal of Medicinal Chemistry 22(11):1380-1384.
46. Temple R. 2006. Hy's law: Predicting serious hepatotoxicity. Pharmacoepidemiology and Drug Safety 15(4):241-243.
47. Ulbricht C, Basch E, Weissner W, Hackman D. 2006. An evidence-based systematic review of herb and supplement interactions by the Natural Standard Research Collaboration. Expert Opinion on Drug Safety 5(5):719-728.
48. Ulrich RG. 2007. Idiosyncratic toxicity: A convergence of risk factors. Annual Reviews in Medicine 58:17-34.
49. US Food and Frug Administration. 2001. FDA warns consumers not to use the dietary supplement LipoKinetix. College Park, MD: Center for Food Safety and Applied Nutrition, Office of Nutritional Products, Labeling, and Dietary Supplements, US Food and Drug Administration. 19 November 2001 (available at: http://www.cfsan.fda.gov/dms/dslipo.html).
50. Venkataramana D, Krishna DR. 1992. High-performance liquid chromatographic determination of usnic acid in plasma. Journal of Chromatography 575(1):167-170.
51. Venkataramana D, Krishna DR. 1993. Pharmacokinetics of d(+)-usnic acid in rabbits after intravenous administration. European Journal of Drug Metabolism and Pharmacokinetics 18(2):161-163.